Investment analysts at StockNews.com assumed coverage on shares of Atrion (NASDAQ:ATRI – Get Free Report) in a research report issued to clients and investors on Thursday. The brokerage set a “sell” rating on the medical instruments supplier’s stock.
Atrion Stock Performance
NASDAQ:ATRI opened at $459.92 on Thursday. The stock’s 50-day simple moving average is $458.90 and its 200 day simple moving average is $444.77. The company has a market cap of $809.46 million, a P/E ratio of 43.23 and a beta of 0.69. Atrion has a 52-week low of $274.98 and a 52-week high of $503.24.
Atrion (NASDAQ:ATRI – Get Free Report) last announced its quarterly earnings results on Thursday, August 8th. The medical instruments supplier reported $0.23 earnings per share for the quarter. The firm had revenue of $48.77 million for the quarter. Atrion had a return on equity of 7.75% and a net margin of 10.60%.
Hedge Funds Weigh In On Atrion
About Atrion
Atrion Corporation, together with its subsidiaries, develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmic applications in the United States, Canada, Europe, and internationally. The company's fluid delivery products include valves that fill, hold, and release controlled amounts of fluids or gasses for use in various intubation, intravenous, catheter, and other applications in the anesthesia and oncology fields, as well as promote infection control in hospital and home healthcare environments.
Further Reading
- Five stocks we like better than Atrion
- How to Buy Cheap Stocks Step by Step
- Analysts Predict 85% Upside for Wave Life Sciences After Rate Cut
- What is a Secondary Public Offering? What Investors Need to Know
- FedEx Stock Dips: Another Reason to Fear Recession Is Near
- High Flyers: 3 Natural Gas Stocks for March 2022
- The Half-Penny Revolution: Will SEC’s Reform Benefit Investors?
Receive News & Ratings for Atrion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atrion and related companies with MarketBeat.com's FREE daily email newsletter.